--- title: "UBT251: Phase 2 Results and the 19.7% Weight-Loss Claim" url: https://www.bodyhackguide.co/blog/ubt251-phase-2-results description: "UBT251 phase 2: 205 participants, 24 weeks, 19.7% maximum mean weight loss. Read the published evidence and why cross-trial rankings mislead." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Image: UBT251: Phase 2 Results and the 19.7% Weight-Loss Claim (https://www.bodyhackguide.co/assets/ubt251-research-G5taMwz9.jpg) Research 4 min read Oct 21, 2026 Fact-checked (https://www.bodyhackguide.co/editorial-standards) # UBT251: Phase 2 Results and the 19.7% Weight-Loss Claim UBT251 phase 2: 205 participants, 24 weeks, 19.7% maximum mean weight loss. Read the published evidence and why cross-trial rankings mislead. B BodyHackGuide Evidence notes from published research and trial registries. Educational information, not medical or dental advice. Key Takeaway **UBT251 is an investigational GLP-1, GIP and glucagon receptor agonist.** A Chinese phase 2 trial in 205 adults without type 2 diabetes reported up to 19.7% mean weight loss at 24 weeks, versus 2.0% with placebo. That is a trial result, not a prediction for an individual or proof that UBT251 beats retatrutide. Evidence checked October 21, 2026. This page explains human research, not purchasing, dosing or self-administration. ## What is UBT251? The three receptor targets put UBT251 in the same broad mechanism category as retatrutide. They do not make the molecules interchangeable. Our comparison below keeps each result attached to its own study rather than treating a receptor count as a performance score. The published paper is UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity (https://doi.org/10.1016/j.cmet.2026.09.021), in _Cell Metabolism_. Its publisher page is dated October 7, 2026. An earlier company announcement came out on February 24, 2026. The evidence is no longer just a press-release headline. ## What did the 24-week trial find? We separate the treatment-group result from the placebo-adjusted difference. Both are useful; they answer different questions. | Measure | Published phase 2 result | How to read it | | --- | --- | --- | | Participants | 205 adults in China, without type 2 diabetes | A defined trial population, not all people with obesity | | Follow-up | 24 weeks | Does not establish multi-year durability | | Mean weight change across UBT251 arms | −13.6% to −19.7% | 19.7% belongs to the best-performing arm | | Placebo mean weight change | −2.0% | The within-study reference group | | Greatest placebo-adjusted difference | −17.7 percentage points | 19.7 minus 2.0, not another treatment-arm result | | 95% confidence interval for that difference | −20.8 to −14.6 percentage points | Statistical uncertainty around the estimate | Source: published randomized phase 2 paper (https://www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00434-1). The word _mean_ matters. Some participants lost more and some less. “Up to 19.7%” describes the largest group mean reported, not the maximum individual loss and not the average across every UBT251 arm. ## UBT251 versus retatrutide: what can we compare? Mechanisms and study designs can be compared. Superiority cannot be established by placing headline percentages beside each other. Our retatrutide Phase 3 evidence card (https://www.bodyhackguide.co/guides/retatrutide-phase-3-card) separates results for people who stayed on treatment from analyses counting everyone who started. Before comparing any UBT251 number with that card, check population, follow-up length and the analysis used. A 24-week placebo-controlled study and an 80-week study answer different questions. The UBT251 trial did not randomize participants against retatrutide or tirzepatide. It therefore cannot establish which of those treatments performs better. ## Safety evidence and the missing pieces The paper identifies gastrointestinal symptoms as the most frequent adverse events, generally mild to moderate. We have not reproduced arm-specific adverse-event percentages here because a useful safety comparison needs the full denominators and discontinuation counts, not an isolated reassuring phrase. A 205-person, 24-week study is not enough to settle rare harms, long-term outcomes or what happens after treatment stops. Participants without type 2 diabetes also do not establish the same result in people with diabetes. The Chinese trial registry (https://clinicaltrials.gov/study/NCT07177469) records actual enrollment of 205. A separate global phase 2 registry (https://clinicaltrials.gov/study/NCT07395687) lists estimated enrollment of 333. That planned number is not an efficacy finding. We keep registrations separate from reported results. ## Sources and related research - Published UBT251 phase 2 paper: https://doi.org/10.1016/j.cmet.2026.09.021 - February 24, 2026 company announcement: https://www.globenewswire.com/news-release/2026/02/24/3243205/0/en/novo-nordisk-triple-agonist-ubt251-delivers-up-to-19-7-mean-weight-loss-after-24-weeks-in-phase-2-trial-in-china.html - Chinese trial registration: https://clinicaltrials.gov/study/NCT07177469 - Global trial registration: https://clinicaltrials.gov/study/NCT07395687 - Eloralintide: a different mechanism and a 48-week trial: https://www.bodyhackguide.co/blog/eloralintide-phase-2-results - Retatrutide trial FAQ: https://www.bodyhackguide.co/guides/retatrutide-faq ## Frequently asked No. Both target GLP-1, GIP and glucagon receptors, but they are different investigational molecules. Shared targets do not establish equal efficacy or safety. ## Related Articles Research ### Eloralintide: Amylin and the Phase 2 Weight-Loss Results Read https://www.bodyhackguide.co/blog/eloralintide-phase-2-results Research ### P11-4 and Curodont: What Enamel-Repair Trials Show Read https://www.bodyhackguide.co/blog/p11-4-enamel-repair-evidence ## New guides, by email New compound guides and research notes when we publish them. No set schedule. Unsubscribe anytime. No spam. Unsubscribe anytime. Share this article: 𝕏 / Twitter (https://twitter.com/intent/tweet?text=UBT251%3A%20Phase%202%20Results%20and%20the%2019.7%25%20Weight-Loss%20Claim&url=https%3A%2F%2Fwww.bodyhackguide.co%2Fblog%2Fubt251-phase-2-results) B BodyHackGuide (https://www.bodyhackguide.co/about)Research editorial Join r/BodyHackGuide on Reddit: https://reddit.com/r/bodyhackguide Join Discord: https://discord.gg/Mhq5UdRYBA | About the author: https://www.bodyhackguide.co/about Back to all articles: https://www.bodyhackguide.co/blog Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://www.bodyhackguide.co/blog" }, { "@type": "ListItem", "position": 3, "name": "UBT251: Phase 2 Results and the 19.7% Weight-Loss Claim" } ] }, { "@context": "https://schema.org", "@type": "BlogPosting", "headline": "UBT251: Phase 2 Results and the 19.7% Weight-Loss Claim", "description": "UBT251 phase 2: 205 participants, 24 weeks, 19.7% maximum mean weight loss. Read the published evidence and why cross-trial rankings mislead.", "image": "/assets/ubt251-research-G5taMwz9.jpg", "datePublished": "2026-10-21T05:52:00Z", "dateModified": "2026-10-21T05:52:00Z", "author": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co/about" }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/bhglogo.png" } }, "mainEntityOfPage": "https://www.bodyhackguide.co/blog/ubt251-phase-2-results", "wordCount": 690, "timeRequired": "PT4M", "articleSection": "Research", "inLanguage": "en-US", "isAccessibleForFree": true, "speakable": { "@type": "SpeakableSpecification", "cssSelector": [ "h1", ".blog-tldr", "article p:first-of-type" ] } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Is UBT251 the same as retatrutide?", "acceptedAnswer": { "@type": "Answer", "text": "No. Both target GLP-1, GIP and glucagon receptors, but they are different investigational molecules. Shared targets do not establish equal efficacy or safety." } }, { "@type": "Question", "name": "Why do sources quote 19.7% and 17.7%?", "acceptedAnswer": { "@type": "Answer", "text": "19.7% is the greatest reported mean weight loss in a UBT251 treatment arm. The 17.7 percentage-point figure subtracts the placebo group's 2.0% loss. They are different measures from the same trial." } }, { "@type": "Question", "name": "Has the UBT251 phase 2 result been published?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. The Cell Metabolism paper has DOI 10.1016/j.cmet.2026.09.021. It is distinct from the February 2026 company topline announcement." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 273 compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```